Analysis of economic efficiency of iron deficiency anemia therapy in patients with malignant tumors
Open Access
- 19 July 2021
- journal article
- research article
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 20 (2) , 59-63
Abstract
Introduction. Correction of iron deficiency anemia in patients with malignant neoplasms is an important aspect affecting the quality of life and the effectiveness of special treatments. At the same time, the therapy of comorbid conditions significantly increases the cost of treating cancer patients.The aim of the study was to conduct a comparative pharmacoeconomic analysis of the two most common methods for correcting iron deficiency anemia in cancer patients: transfusion of erythrocyte suspension and intravenous iron preparations using iron carboxymaltose as an example.Materials and methods. An observational, analytical, cohort study was carried out, which included 120 cancer patients. The patients underwent laboratory examination. The tests were assessed: a general blood test with an assessment of the morphological characteristics of erythrocytes, serum iron, ferritin, CRP, total protein. An analysis of the costs of iron deficiency anemia therapy was carried out, taking into account the procurement cost of drugs.Results. It is economically more profitable to use intravenous iron preparations in comparison with transfusion of erythrocyte suspension for the treatment of iron deficiency anemia in patients with malignant neoplasms. The cost of correcting iron deficiency anemia per patient was: when treated with carboxymaltosate iron (Ferinject): 7943.96 rubles, with transfusion of erythrocyte suspension: 16856.40 rubles.Conclusion. In the treatment of anemia in patients with malignant neoplasms with blood preparations (erythrocyte suspension), an improvement in hematological parameters is noted earlier and to a greater extent than with the use of iron preparation carboxymaltozate («Ferinject»). Nevertheless, the duration of the clinical effect when using erythrocyte suspension is lower than that of a parenteral iron preparation.Keywords
This publication has 10 references indexed in Scilit:
- Практические рекомендации по лечению анемии при злокачественных новообразованияхMalignant tumours, 2021
- The use of intravenous ferric carboxymaltose without erythropoiesis-stimulating agents in the treatment of anemia in cancer patients undergoing chemotherapy with or without radiotherapyAnnals of Oncology, 2019
- Effectiveness and safety of ferric carboxymaltose to treat iron deficiency anemia in cancer patients.Journal of Clinical Oncology, 2019
- Intravenous ferric carboxymaltose treatment in cancer patients.Journal of Clinical Oncology, 2016
- Anemias in Oncology: Potential of Maintenance TherapyClinical oncohematology, 2016
- Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemiaAnnals of Oncology, 2012
- Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial dataBMC Hematology, 2011
- Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for useAnnals of Oncology, 2010
- The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsEuropean Journal of Cancer, 2004
- Prevalence and outcomes of anemia in cancer: a systematic review of the literatureThe American Journal of Medicine, 2004